Industry · Medical Devices
The medical device market keeps growing, but manufacturers face a surge of AI-enabled products, heavy tariff costs, new device-cybersecurity rules and careful capital buyers. For the companies that sell to medtech, that means technical, regulated, multi-stakeholder buying. Coral Blue Data helps you find the right manufacturers and accounts and fuel demand and lead generation that fits how medtech buys today.
Medical device industry trends 2026
Across market forecasts, executive surveys and regulatory updates, the same themes keep surfacing. Each one changes what medtech companies buy, who signs off and how long it takes.
Projected global medical device market in 2026, growing about 7% a year
Ageing populations and rising chronic disease keep demand climbing toward an estimated $818B by 2031. The market is healthy — but buyers remain disciplined on cost.
So what: there is budget to win, for offers that clearly improve cost or outcomes.
Source: MarketsandMarkets
AI-enabled medical devices authorised by the FDA for the US market, as of September 2026
AI has moved from novelty to norm in device pipelines. Medtech executives rank AI-enabled platforms among the top growth drivers for the year ahead.
So what: demand is rising for the data, tooling and validation that bring AI devices to market.
Source: FDA data, via MedTech Dive
Estimated annual tariff impact on the largest medtech companies
Tariffs have become one of the most persistent cost pressures in medtech, pushing manufacturers to rethink sourcing, pricing and where they build.
So what: cost, resilience and supply-chain offers get a close hearing right now.
Medtech leaders naming AI implementation their primary cost-containment strategy for 2026
Under margin pressure, manufacturers are turning to AI to drive efficiency across operations, quality and development — not just into the devices themselves.
So what: operational AI and efficiency tooling have a receptive audience.
Connected medical and IoT devices in hospitals carrying known critical vulnerabilities
With most fielded devices falling short of the FDA's latest cybersecurity expectations, security is now built into premarket submissions and hospital purchasing alike.
So what: security and compliance review sit inside device design and sales.
Medtech and biopharma executives confident in their own 2026 financial outlook
Deloitte finds leaders broadly optimistic, tempered by geopolitical, pricing and regulatory caution. Investment continues, but with a sharper eye on returns.
So what: buyers will invest — if you make the value and risk case clearly.
Hospitals run a large base of exposed, legacy and vulnerable connected devices. That reality — plus tougher FDA expectations — pushes security into device design, procurement and every vendor review.
So what: manufacturers and their suppliers must answer security questions by design.
Connected-device security exposure in hospitals (2025)
Last updated: November 2026
What it means for you
The market is growing, but buying is technical, regulated and cost-conscious. Engineering, regulatory, operations, IT and procurement all weigh in, and buyers expect you to understand compliance and the product. Growth now depends on precision and credibility.
Engineering, regulatory, operations, IT and procurement all review purchases. Reaching one technical champion is no longer enough.
Quality systems, FDA requirements and device-cybersecurity rules sit inside design and sourcing decisions.
Tariffs and margin pressure push buyers to demand clear savings, resilience or outcome improvements before they commit.
With connected devices a growing risk, product security and vendor-risk review now start early, not at the end.
Sourcing shifts and reshoring move suppliers and decision-makers, making account and contact data go stale fast.
Many tools now claim AI and regulatory readiness. Generic outreach is ignored; proof and specificity win.
Questions medtech growth teams are asking
How we help
In medtech, these three only work when they build on each other. Accurate account data shows you where to play; demand generation earns attention from technical and regulatory stakeholders; lead generation turns that attention into qualified conversations.
Step 1 · Data
"Where should we focus?"
Step 2 · Demand generation
"How do we get on their radar?"
Step 3 · Lead generation
"Who do we talk to this week?"
Coral Blue Data provides the medtech data foundation — accounts, contacts, enrichment and hygiene — that powers your demand and lead generation programmes, whether you run them in-house or with an agency. Talk with a medtech data expert →
Buyer personas
These personas represent the teams that sell into medical device manufacturers most often. Each faces a different version of the 2026 market. Here is how data, demand generation and lead generation change the outcome for each.
Business Development · Components, materials & contract manufacturing
Goal
Win supply and manufacturing agreements as medtech resets its supply chain.
What they're facing
How we help
Reach supply-chain, procurement and operations leaders by segment, modality and plant.
Lead with quality, reliability and total-cost content for technical and procurement buyers.
Focus on manufacturers actively reshaping where and how they build.
Outcome: a pipeline matched to device makers rethinking their supply base.
Head of Growth · QMS, PLM & AI/ML development tools
Goal
Help device makers build AI-enabled products and run leaner operations.
What they're facing
How we help
Target by segment and R&D maturity; reach engineering, quality and digital leaders.
Share validated results and compliance-ready content with technical buyers.
Prioritise makers investing in AI-enabled devices and operations.
Outcome: outreach that cuts through AI noise and reaches teams ready to buy.
Demand Gen Manager · Product-security & compliance for devices
Goal
Help device makers meet FDA cybersecurity expectations by design.
What they're facing
How we help
Reach product-security, engineering and regulatory leaders by segment and device class.
Educate with premarket-cyber and risk content aimed at each stakeholder.
Segment by device type and connectivity to match your offer to each maker.
Outcome: earlier conversations and a message that fits each maker's compliance reality.
VP Sales · RA/QA consulting, testing & clinical evidence
Goal
Win regulatory, quality and evidence work as AI devices and rules multiply.
What they're facing
How we help
Reach regulatory, quality and clinical leaders by segment and device class.
Share speed-to-approval and compliance content for RA/QA and leadership.
Prioritise makers with active submissions matched to your expertise.
Outcome: conversations with makers whose programmes fit what you do best.
Business Development · Engineering & regulatory staffing
Goal
Help device makers fill engineering, regulatory and quality roles.
What they're facing
How we help
Reach engineering, regulatory and HR leaders by segment, size and region.
Position your talent model to engineering and operations leaders together.
Focus outreach on makers scaling teams around AI and new products.
Outcome: more conversations with the leaders who own hiring and capability.
Personas are illustrative composites based on common medtech go-to-market teams, not specific individuals.
The medtech buying group
Most medtech purchases now pass through several hands across engineering, regulatory and operations. Effective demand and lead generation speaks to each of them in their own terms.
Design, systems and software engineers judge technical fit, performance and integration.
RA/QA leaders assess compliance, validation and the impact on approvals.
Manufacturing and sourcing leaders weigh capacity, cost, resilience and supplier risk.
IT and product-security leaders assess data, connectivity and cyber risk by design.
Compare price, terms and payback, and weigh tariff and total-cost impact.
The most discussed trends are a growing market led by ageing demographics, a surge of AI-enabled devices, heavy tariff and cost pressure, tougher device-cybersecurity expectations, and cautious optimism among executives.
Buying is technical, regulated and cost-conscious. Expect multi-stakeholder cycles across engineering, regulatory, operations, IT and procurement, with security and compliance review built into design and sourcing decisions.
Connected devices are a growing attack surface and the FDA now expects cybersecurity to be built into premarket submissions. Security has moved from an afterthought to a design requirement and a vendor-selection criterion.
Demand generation creates interest across your target market. Lead generation captures and qualifies specific accounts and people ready for a sales conversation. In medtech, both depend on accurate account and contact data.
Start by mapping target makers and their full buying group across engineering, regulatory and operations. Then tailor messages by role — technical proof for engineering, compliance for regulatory, ROI for procurement — and stay visible through long, technical evaluations.
We supply the medtech data foundation: account and contact data across device segments and the companies that serve them, plus enrichment, cleansing and verification to keep it current for your campaigns and outreach.
Tell us who you sell to and what you're trying to grow. We'll show you the device makers and buying groups that fit, and how to put that data to work in your demand and lead generation.
A specialist reviews every request and replies by email, typically within two business days.
Sources
